Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
Stocks · News reference
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted five new employees 314,000 RSUs and options to purchase 92,400 shares as inducement for employment. The RSUs vest over four years, while stock options have a $5.70 exercise price and 10-year term with four-year vesting schedule.
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.